Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORTITUDE-101 bemarituzumab in first-line FGFR2b-overexpressing advanced gastric or gastroesophageal junction cancer
2021-003461-35Phase 3Active
- Sponsor
- Amgen
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric cancer (GC) and esophagogastric junction cancer comparing Bemarituzumab plus mFOLFOX6 with Placebo plus mFOLFOX6 (2 arms). Primary endpoint: Overall survival. Started Nov 2021; status: active.
02
Drugs
bemarituzumab
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on 2021-003461-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003461-35.